KAS
PCRX icon

Kestra Advisory Services’s Pacira BioSciences PCRX Stock Holding History

Kestra Advisory Services’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,869
Closed -$48.4K – 4040
2025
Q4 		$48.4K Buy
+1,869
New +$44.4K ﹤0.01% 3961
2025
Q2 		– Sell
-11,852
Closed -$295K – 2946
2025
Q1 		$295K Sell
11,852
-4,044
-25% -$96.8K ﹤0.01% 2181
2024
Q4 		$299K Buy
+15,896
New +$279K ﹤0.01% 2219
2021
Q2 		– Sell
-3,672
Closed -$257K – 2026
2021
Q1 		$257K Buy
3,672
+111
+3% +$7.93K ﹤0.01% 1563
2020
Q4 		$209K Buy
+3,561
New +$209K ﹤0.01% 1693

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kestra Advisory Services's PCRX Position: Q1 2026 in Review

Kestra Advisory Services sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 1,869 shares — an estimated $48.4K sold.

Kestra Advisory Services first reported a position in PCRX in Q4 2020 and held it in 5 quarters. The position peaked at $299K in Q4 2024. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Kestra Advisory Services reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 1,869 Pacira BioSciences shares in Q1 2026, an estimated $48.4K.
  • Kestra Advisory Services first reported a position in Pacira BioSciences in Q4 2020 and held it in 5 quarters.
  • Kestra Advisory Services's Pacira BioSciences position peaked at $299K in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.